B & T Capital Management DBA Alpha Capital Management Buys New Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

B & T Capital Management DBA Alpha Capital Management purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 12,223 shares of the company's stock, valued at approximately $416,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CRSP. Wood Tarver Financial Group LLC purchased a new stake in CRISPR Therapeutics during the fourth quarter worth about $30,000. Ameriflex Group Inc. acquired a new position in CRISPR Therapeutics during the fourth quarter worth approximately $36,000. NBC Securities Inc. increased its position in CRISPR Therapeutics by 156,300.0% during the first quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock worth $53,000 after purchasing an additional 1,563 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $71,000. Finally, GAMMA Investing LLC increased its position in shares of CRISPR Therapeutics by 8,146.2% in the first quarter. GAMMA Investing LLC now owns 4,288 shares of the company's stock worth $146,000 after acquiring an additional 4,236 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP traded down $3.69 during midday trading on Tuesday, hitting $52.73. 3,109,291 shares of the company's stock traded hands, compared to its average volume of 1,954,214. The firm has a fifty day moving average of $42.52 and a 200 day moving average of $41.28. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of -11.67 and a beta of 1.82. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $63.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the previous year, the business posted ($1.43) earnings per share. The firm's revenue for the quarter was up 71.6% compared to the same quarter last year. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Naimish Patel sold 3,932 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider directly owned 6,068 shares of the company's stock, valued at $218,083.92. The trade was a 39.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Barclays decreased their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Chardan Capital reiterated a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Thursday, June 26th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Needham & Company LLC reaffirmed a "buy" rating and set a $81.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.